Redpoint Bio Corporation, a development stage biotechnology company, focuses on the development of healthier foods and new approaches for the treatment of diabetes and obesity by understanding the biology of taste and its relationship to metabolism, satiety, and diabetes. It enters into a license and commercialization agreement with International Flavors and Fragrances Inc. for the development, manufacture, use, and commercialization of RP44, which is a component of the stevia plant that works as a sweetness enhancer amplifying the existing sugary sweetness in a food or beverage. The company is based in Philadelphia, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:RPBC
CUSIPN/A
Phone215-456-2312
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares79,920,000
Market Cap$0.11
Redpoint Bio (OTCMKTS:RPBC) Frequently Asked Questions
What is Redpoint Bio's stock symbol?
Redpoint Bio trades on the OTCMKTS under the ticker symbol "RPBC."
What is the consensus analysts' recommendation for Redpoint Bio?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Redpoint Bio in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Redpoint Bio's key competitors?
Some companies that are related to Redpoint Bio include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE) and Eloxx Pharmaceuticals (ELOX).
Who are Redpoint Bio's key executives?
Redpoint Bio's management team includes the folowing people:
- Dr. R. Kyle Palmer Ph.D., Sr. Director of Discovery Research
Has Redpoint Bio been receiving favorable news coverage?
Headlines about RPBC stock have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Redpoint Bio earned a coverage optimism score of 0.04 on Accern's scale. They also gave news stories about the company an impact score of 43.35 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Redpoint Bio?
Shares of RPBC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Redpoint Bio's stock price today?
One share of RPBC stock can currently be purchased for approximately $0.0014.
How big of a company is Redpoint Bio?
Redpoint Bio has a market capitalization of $110,000.00.
How can I contact Redpoint Bio?
Redpoint Bio's mailing address is 7 GRAPHICS DRIVE, EWING NJ, 08628. The company can be reached via phone at 215-456-2312.
MarketBeat Community Rating for Redpoint Bio (OTCMKTS RPBC)
MarketBeat's community ratings are surveys of what our community members think about Redpoint Bio and other stocks. Vote "Outperform" if you believe RPBC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPBC will underperform the S&P 500 over the long term. You may vote once every thirty days.
